Research You are here:HomeOur servicesList of servicesGastroenterology and HepatologyResearch Overview • IBD • Liver • Oesophageal The clinical research program in oesophageal diseases is focused firstly on diagnostics, aiming to improve the utility of the diagnostic methodology used to assess oesophageal structure and motor function (e.g. endoscopy, barium swallow, manometry, and ambulatory reflux monitoring). Secondly, our research aims to improve therapeutic options for patients with oesophageal diseases including oesophageal motility disorders (e.g. achalasia), eosinophilic oesophagitis, oesophageal strictures, gastro-oesophageal reflux disease, and oesophageal dysfunction related to systemic disease (e.g. end-stage lung disease/ lung transplantation, and systemic sclerosis). Selected publications Jacob R, Danta M, Feller R, Williams D, Sanagapalli S. Empiric esophageal dilatation for solid-food dysphagia: Presence of mucosal tear on relook endoscopy predicts symptomatic response. The American Journal of Gastroenterology. Online ahead of print 2023. Sanagapalli S, Plumb A, Lord RV, Sweis R. How to effectively use the barium swallow: current role in oesophageal dysphagia. Neurogastroenterology & Motility. 2023;00:e14605 Sanagapalli S, Sweis R, Fox M. How provocative tests in addition to wet swallows during high-resolution manometry can direct clinical management. Current Opinion in Gastroenterology. 2022; 38(4):402 Sanagapalli S, Sweis R. Esophageal function lumen imaging probe Vs Highresolution manometry – the jury is still out. American Journal of Gastroenterology. 2022; 117:356 • High risk Pancreas Cancer Screening in high risk individuals Drs Alina Stoita and David Williams commenced the national pancreatic cancer screening program in high risk individuals at St Vincent's Hospital in 2010. Since then the program has expanded to Queensland (Royal Brisbane Hospital), Victoria (Epworth Hospital, Royal Melbourne Hospital, Austin Hospital) and Western Australia (Sir Charles Gairdner Hospital). The screening protocols are in accordance with the International Cancer of the Pancreas Consortium recommendations. People are considered at higher risk of pancreatic due to family history (>2 close family members with pancreatic cancer) or having a known gene mutation (eg. BRAC2/PALB2/Lynch syndrome) in addition to a family history of pancreatic cancer or by having certain clinical disorders (eg, Peutz- Jeghers Syndrome or Hereditary Pancreatitis). The program involves genetic counselling +/- testing if appropriate, blood tests, endoscopic ultrasound and MRI. For more information on the program, please contact the NSW coordinator t.dwarte@garvan.org.au https://www.pancreaticcancer.net.au/research-familial/screening-trial/ Selected publications Stoita A, RS O'Neill. "Biomarkers in diagnosis of pancreatic cancer: are we closer to finding the golden ticket?" World Journal of Gastroenterology July 2021, 27 (6) 4045-4087 Stoita A, K Murali, Dwarte T. "Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer screening program " Hereditary cancer in Clinical practice, 2021, 19:33 Stoita A, RS O'Neill, B Meissner, S Emmanuel. " Long term positive psychological outcomes in an Australian pancreatic cancer screening program " Familial Cancer, Oct 2019 Stoita A, T Dwarte, S Simpson, et al. " Genetic counselling and personalised risk assessment in an Australian pancreatic cancer screening program" Hereditary Cancer in Clinical Practice, 2019